Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines, has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 14, 2025, at 9:00 a.m. PT/12:00 p.m. ET in San Francisco, California.

The company's Founder, President and CEO, Nello Mainolfi, PhD, will present an overview of Kymera's progress and outline anticipated milestones for 2025. Interested parties can access a live webcast of the presentation and Q&A session through the 'News and Events' section of Kymera's investor relations website. The presentation recording will be archived and available for later viewing.

WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 14, 2025, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, PhD, Founder, President and CEO, will provide an overview of the Company’s progress and anticipated milestones for 2025.

A live webcast of the presentation and Q&A session will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.

About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.

Investor and Media Contact: 

Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300 

FAQ

When is Kymera Therapeutics (KYMR) presenting at the J.P. Morgan Healthcare Conference 2025?

Kymera Therapeutics will present on Tuesday, January 14, 2025, at 9:00 a.m. PT/12:00 p.m. ET at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.

How can investors watch Kymera's (KYMR) J.P. Morgan Healthcare Conference presentation?

Investors can watch the live webcast through the 'News and Events' section in the Investors area of Kymera's website at www.kymeratx.com. A replay will be available after the event.

What topics will be covered in Kymera's (KYMR) J.P. Morgan presentation?

The presentation will cover Kymera's progress and anticipated milestones for 2025, delivered by CEO Nello Mainolfi, PhD.

Will Kymera Therapeutics (KYMR) provide a Q&A session at the J.P. Morgan Healthcare Conference?

Yes, the presentation will include a Q&A session, which will be available via live webcast and archived for later viewing.